FIELD: biotechnology, immunology.
SUBSTANCE: patient mononuclear cells are cultivated in presence of antigen selected from group containing myelin protein, collagen proteins, allergen, allogenic cells. Antigen-reactive blast T-cells are separated by using gradient centrifugation. Vaccine of present invention makes it possible to treat immunological disorders for 10-12 days.
EFFECT: new T-cell vaccine for treatment of immunological disorders associated with antigen presence.
5 cl
| Title | Year | Author | Number |
|---|---|---|---|
| T-CELLULAR VACCINE FOR CEREBROSPINAL SCLEROSIS TREATMENT | 1998 |
|
RU2209633C2 |
| METHOD FOR IMMUNOTHERAPY OF CHRONIC REFRACTORY HERPES VIRUS INFECTION | 2011 |
|
RU2485962C1 |
| APPLICATION OF Fc-FRAGMENTS OF IMMUNOGLOBULIN CLASS G AS ANTIGEN FOR TREATING RHEUMATOID ARTHRITIS, REMEDY AND METHOD OF TREATING | 2008 |
|
RU2385164C1 |
| METHOD FOR IMMUNE THERAPY OF CHRONIC VIRAL HEPATITIS C | 2016 |
|
RU2637631C2 |
| AUTOLOGOUS VACCINE FOR ONCOTHERAPY AND METHOD FOR PREPARING THEREOF | 2008 |
|
RU2392946C2 |
| MATERIALS AND METHODS REFERRING TO T-CELLULAR VACCINES | 2002 |
|
RU2302257C2 |
| METHOD FOR PREPARING AUTOLOGOUS TUBERCULOSIS VACCINE | 2008 |
|
RU2372936C1 |
| RELEASE AND IDENTIFICATION OF T-CELLS | 2003 |
|
RU2327487C2 |
| METHOD FOR IMMUNOTHERAPY OF CEREBRAL MALIGNANT TUMORS | 2004 |
|
RU2262941C2 |
| METHOD OF IMMUNOTHERAPY MALIGNANT TUMORS OF BRAIN | 2018 |
|
RU2686756C1 |
